Dalrada taps Captain David Bacon to its board as it advances its health product lines

Dalrada Corporation (OTCQB:DFCO) said that it has appointed well-known medical expert and US Navy Captain Dr David Bacon to the company’s board, as the group focuses on advancing Dalrada Health’s product lines.  Dr Bacon is an active US Navy Captain with 22 years of service. During the coronavirus (COVID-19) pandemic, Dr Bacon was responsible for reviewing proposals for funding in the areas of therapeutics, diagnostics, and wearable monitors. He reviewed more than 400 proposals and provided his expert opinion on the scientific rationale and study design, said the company.  The senior US officer has been working on infectious disease research for more than two decades. After graduate school, he started a post-doctoral fellowship in the Enteric Disease Department at the Naval Medical Research Center (NMRC), in Silver Spring and was commissioned as a lieutenant in 1999. READ: Dalrada Corporation sees FY3Q revenue jump triple digits year-over-year as growth accelerates After September 11, 2001, Dr Bacon trained as an officer-in-charge of a bio-warfare detection team in support of the Biological Defense Research Directorate at NMRC. Dr Bacon deployed as element commander of a biological weapons detection lab, in Baghdad, Iraq. He was also a member of the scientific assessment team commissioned by the Iraq Survey Group to investigate biological weapons programs in Iraq. Dr Bacon has been the former program area manager, for the US Department of Defense’s HIV and Emerging Infectious Diseases research programs. In a statement, Dalrada CEO Brian Bonar said: “We are thrilled that Dr Bacon has accepted a role with Dalrada’s Board of Directors. His extensive background of conducting, directing, and developing evidence-based research will be extremely valuable insight for accelerated availability of Dalrada Health’s product lines.” Dalrada said Dr Bacon now joins CEO Bonar, Tom Giles, Pauline Gourdie, Harvey Herskowitz, Brian Kendrick, Fawad Nisar, Fletcher Robbe and Anthony Zolezzi on the company’s board. Contact the author Uttara Choudhury at uttara@proactiveinvestors.com Follow her on Twitter: @UttaraProactive